News Headlines Article

Medicare Says It Will Pay for Expensive Prostate Drug
New York Times

Medicare announced on Wednesday that it would pay for Dendreon’s prostate cancer drug Provenge, whose $93,000 price tag had ignited debate about the cost and effectiveness of cancer drugs. The Centers for Medicare and Medicaid Services said in a memo posted on its Web site that Provenge was a “reasonable and necessary” treatment for Medicare patients who had the stage of prostate cancer for which the drug was approved by the Food and Drug Administration last April.

Commands